BioLineRx Ltd. Annual Report - How They Did This Year

Hey there! Thinking about BioLineRx Ltd. as an investment? Let's review their past year's performance, ending December 31, 2025. We'll explain it simply, without confusing financial terms. We'll look at what they do, how they made money (or didn't), any big wins or bumps in the road, and what the future might hold.

Here's what we'll cover:

1. What does this company do and how did they perform this year? BioLineRx develops "life-changing therapies" for cancer and rare diseases. They advance new drug candidates, often with partners. Their goal is to meet significant unmet medical needs.

   Their big news is APHEXDA® (motixafortide), their first approved product. The FDA approved this drug on September 8, 2023, in the U.S. It helps with stem-cell mobilization for bone marrow transplants. This treats multiple myeloma, a blood cancer. This marks a big step for any biotech company. They moved from pure research to selling a product.

   They don't sell APHEXDA directly everywhere. They use partners:

   • Ayrmid Pharma Ltd. sells it worldwide, excluding Asia. This partnership began in November 2024. BioLineRx then stopped its own U.S. sales efforts. This big strategic shift let them focus on development in Israel. It also greatly reduced their annual cash spending.
   • Auspex Bioscience (Gloria) sells it in Asia. This partnership started in October 2023.

   Beyond APHEXDA, they develop motixafortide for other uses. These include pancreatic cancer and other solid tumors outside Asia. These are early-stage developments. They could drive future growth.

   In September 2025, they started a new collaboration. They partnered with Hemispherian AS for GLIX1. This drug could treat glioblastoma, a serious brain cancer, and other cancers. This expands their drug pipeline beyond motixafortide. They explore new ways to treat tough cancers.

2. Financial performance - sales, profit, growth metrics

   • Limited Sales & Losses: This is key for investors. BioLineRx reports "limited sales to date." They have also "incurred significant losses since inception." They expect more losses and "may never be profitable." APHEXDA sales have been small. These sales have not covered their operating costs. Making money from APHEXDA depends on partners Ayrmid and Gloria. They must successfully sell the product. BioLineRx could receive milestone payments and royalties. However, these may take many years, if they happen at all. Even with product sales, they might not become profitable. They could still need more funding. This is common for biotechs focused on R&D. But it is a major risk.
   • Specific Losses: They reported these losses:
     • $60.6 million in 2023
     • $9.2 million in 2024. This was an 84.8% drop from 2023.
     • $2.0 million in 2025. This was an 78.3% drop from 2024. Losses fell quickly over the past two years. This is a positive trend. It largely comes from licensing APHEXDA out. They also cut U.S. sales costs. Still, they are not profitable.
   • Total Losses: As of December 31, 2025, their total losses since starting reached $401 million. This large amount shows the long, costly path typical for drug development.
   • Sales Sources: They get some money from APHEXDA royalties and potential milestone payments from partners. These sales have not covered their costs.
   • Accounting: They report finances using IFRS standards. All figures are in U.S. dollars.
   • Share Count & Dilution: As of March 8, 2026, BioLineRx had 2,610,814,390 ordinary shares. This is a huge number of shares. With so many shares, any profit or company value spreads thin. This can mean a very low value per share for investors. Companies often sell new shares to raise money. This can significantly reduce the value of existing shares. It also makes it harder for the stock price to grow much.

3. Major wins and challenges this year

   • Major Wins:
     • APHEXDA Approved: The U.S. approved APHEXDA on September 8, 2023. This is a huge win. It marks their first product for sale. It also proves their development skills.
     • Smart Licensing Deals: Partnerships with Ayrmid (November 2024) and Gloria (October 2023) are key. They sell APHEXDA. The Ayrmid deal let them stop costly U.S. sales. They refocused on R&D. This directly cut their cash spending and losses. Losses fell from $60.6 million in 2023 to $2.0 million in 2025.
     • GLIX1 Partnership: The Hemispherian partnership for GLIX1 in September 2025 is a big step. It adds a new cancer treatment to their pipeline. This diversifies their drug focus.
   • Challenges & Financial Moves:
     • Always Needing Money: The company constantly seeks funds. They kept using their loan from BlackRock. They took a second $20 million payment in April 2024.
     • Loan Changes: In November 2024, they changed their BlackRock loan. They agreed to pay back $16.5 million. They also canceled future sales-based payments. This helped manage their debt and cut future uncertainty. But it shows ongoing money pressures.
     • ADS Reverse Split: On January 30, 2025, they did a 1-for-40 reverse ADS split. This changed the ratio of ADSs to ordinary shares. It doesn't change your total investment value. But it usually raises the price per ADS. Companies often do this when their stock price is very low. They aim to meet exchange rules, like Nasdaq's minimum price. This can signal financial trouble. It often leads to more negative feelings and a stock price drop after the split.

4. Financial health - cash, debt, liquidity

   • Cash On Hand: As of December 31, 2025, BioLineRx had $20.9 million. This includes cash and short-term bank deposits.
   • Cash Timeline: They believe their current cash will last into the first half of 2027. This gives investors a clear timeline. It shows when they will need more money.
   • "Going Concern" Warning: This is a serious warning for investors. Management doubts the company can continue operating long-term. This means they worry about having enough money to stay in business. Their auditors also noted this risk. If they can't improve cash, they might run out of money. Shareholders could lose most or all their investment. Getting new funding on fair terms could also become very hard.
   • Loan Details (BlackRock):
     • They first took $10 million from BlackRock in September 2022. They took another $20 million in April 2024. They did not use the final $10 million loan portion.
     • In November 2024, they changed the loan. They paid back $16.5 million. They canceled future sales-based payments. They will pay the rest of the loan, principal and interest, over three years. This ends December 1, 2027.
     • The loan's minimum cash rule dropped to $4 million. This gives them more flexibility.
     • They will use 10% of future milestone payments to repay the loan. This applies to payments from licensing deals through December 1, 2027.
   • Debt Risk: If they miss BlackRock payments or default, BlackRock could seize company assets. This includes intellectual property or other collateral. This would be disastrous.
   • Raising Money: They actively raise funds. This includes loans and stock offerings, like the January 2025 Offering. These keep operations running. These actions show their constant need for cash. This cash supports R&D. They will keep looking for other funding sources. But there is no guarantee these will be available. They might not get fair terms, or any at all. This is especially true given the "going concern" warning.
   • Smaller Company: The company is a "Non-accelerated filer." This means its public float is under $700 million. Public float is the value of shares available for trading. This shows it's a smaller company. Its shares may have less liquidity and higher volatility.

5. Key risks that could hurt the stock price Investing in BioLineRx carries high risk. The company itself points out several key risks:

   • Going Concern Doubt: As noted, management doubts the company can keep operating. Their auditors agree. This is a major, basic risk. Shareholders could lose most or all their investment. This happens if the company cannot get more funding or become profitable.
   • No Profit: They have lost money for years. They may never become profitable. Making good sales and profits depends heavily on partners. Ayrmid and Gloria must sell APHEXDA well. They also need milestone payments and royalties. These could take many years, if they happen. Even with product sales, they might still need more money to operate.
   • Not Enough Money: They have cash until mid-2027. But there's no guarantee of more funding on fair terms. This is especially true with the "going concern" warning. Failing to raise money would severely hurt R&D and operations.
   • Loan Default: If they cannot repay BlackRock, they could lose valuable assets. This includes intellectual property or other collateral. This would be disastrous.
   • Share Dilution: They have over 2.6 billion ordinary shares. They constantly raise money by selling new shares and warrants. Existing shareholders could see their ownership value drop. This happens as more shares are issued. The 1-for-40 ADS reverse split in January 2025 did not change ordinary share count. But it often signals a struggling stock price. It can lead to more negative investor feelings and a price drop after the split.
   • Product Acceptance: APHEXDA is approved. But there's no guarantee doctors, patients, or insurers will widely use it. This is vital for sales success. The same applies to GLIX1, if approved.
     • Doctors often hesitate to switch patients from old treatments to new ones.
     • APHEXDA competes with standard stem cell methods. It also competes with cheaper generic versions. This makes market entry very challenging.
     • Teaching doctors and insurers about APHEXDA's benefits costs a lot. It might not even work.
     • Many things affect drug acceptance. These include how it compares to rivals, side effects, ease of use, price, and marketing.
     • The market might be smaller than they expect. Their forecasts rely on "inherently uncertain" assumptions. No independent source has checked these.
   • Problems After Approval: Even approved drugs can later show issues. They might be less effective or have new side effects. This happened with APHEXDA. It was less effective or tolerable than thought. This shows ongoing risks even after approval. Regulators could withdraw approval or force recalls. They might impose restrictions, issue fines, or demand "black box" warnings. The company could also face lawsuits. Its reputation could suffer greatly.
   • Regulatory Hurdles: They might not get more approvals for motixafortide. GLIX1 might not get initial approval. Regulatory processes are long, costly, and uncertain. They need "additional, time-consuming and costly development." Failing to follow rules could mean losing current approvals.
   • Trial Failures: Biotech development is very risky. Clinical trials are long, expensive, and uncertain. Good early results don't guarantee success in later trials. One trial failure can stop a drug's development.
   • Relying on Others: They depend heavily on other companies. These firms handle studies, trials, manufacturing, and more. If these partners fail or miss deadlines, BioLineRx's development could suffer. Product launches could also face delays.
   • Partnership Risks: They might not form or keep partnerships, like licensing deals. Or they might fail to meet in-license agreement terms. They could lose rights to their drug candidates. This would severely hurt their pipeline and future.
   • Competition: Other companies might make better, safer, or cheaper treatments. This would negatively impact BioLineRx's future.
   • Pricing & Coverage: Even if approved, their drugs might face bad pricing rules. Insurers might offer poor coverage. Healthcare reforms could also limit sales. This makes it hard for patients to get their drugs.
   • Product Liability: Drug development carries high risk of lawsuits. If they lack enough insurance, a claim could severely hurt the business. It could also lead to big financial losses.
   • IT & Data Security: Computer system failures or data breaches could harm their business. This could cause delays, reputational damage, and legal issues.
   • IP Risks: Much of their IP comes from agreements. These are with other companies or universities. If these agreements end, or patents are challenged or expire, they could lose drug sales rights.
   • Nasdaq Delisting Risk: Their stock price might stay too low, like below $1.00. Or they might miss other listing rules. Their ADSs could be removed from Nasdaq. This makes trading harder for investors. It could also hurt their ability to raise money.
   • Israel's Situation: The company notes instability in Israel. This includes political, economic, and military issues. A large part of their operations is there. This could affect their business, R&D, and employee safety.
   • Israeli Law: Israeli law might make it harder to acquire the company. This could happen even if it's a good deal for shareholders. Enforcing U.S. judgments in Israel can be tough. Serving legal papers to officers and directors might also be hard. Israeli law governs shareholder rights. These may differ from U.S. laws.

6. Competitive positioning The company faces strong competition. Rivals could offer better, safer, or cheaper treatments. For APHEXDA, main rivals are standard stem cell methods. Cheaper generic versions also compete. BioLineRx and partners must make APHEXDA stand out. This helps gain market share and justify its price.

7. Leadership or strategy changes

   • Big Strategy Change: In November 2024, BioLineRx made a big decision. After the Ayrmid licensing deal, they stopped U.S. sales efforts. They now focus on development in Israel. This targets cancer and rare diseases. This move aimed to cut annual cash spending. It also concentrated resources on R&D. This shift directly cut their losses. Losses fell from $60.6 million in 2023 to $2.0 million in 2025. This shows a major change in how they operate.

8. Future outlook

   • Cash Timeline: They expect current cash to last into mid-2027. This offers a clear timeline for operations. But it also shows their ongoing need for money.
   • Expanding APHEXDA: They actively develop motixafortide for new uses. These include pancreatic cancer and other solid tumors. Success here could greatly expand APHEXDA's market.
   • New Drug: The GLIX1 partnership in September 2025 shows pipeline expansion. They seek new treatments for glioblastoma and other cancers. This aims to diversify future sales.
   • Constant Funding Needs: Their financial plans show ongoing efforts to get money. This includes loans and offerings into 2025. This capital supports future development and operations. They will keep seeking funds from various sources. These include licensing deals, partnerships, and grants. But there's no guarantee these will be available. They might not get fair terms, or any at all.
   • They hope for successful trials, market acceptance, and approvals. They also hope for strong partnerships and enough money. But all these face big risks, as detailed in "Key risks."

9. Market trends or regulatory changes affecting them The company knows healthcare law changes could affect their business. This includes rules in the U.S. or elsewhere. It covers new standards for drug approval, making, and selling.

   They specifically note risks from healthcare reforms. These include lower drug prices. Also, government and insurers might change coverage policies. If insurers don't pay enough for approved drugs, sales and profit could drop. This is true no matter how well a drug works. These trends create an uncertain market for new drugs.

Investing in BioLineRx means betting on their ability to secure future funding, successfully develop their pipeline, and ensure market acceptance for APHEXDA and future drugs, all while navigating significant financial and operational risks.